US FDA explains process for disqualifying clinical investigators
This article was originally published in SRA
The US Food and Drug Administration has issued revised guidance explaining the administrative procedure followed by the agency for disqualifying clinical investigators involved in wrongdoing from participating in studies involving investigational drugs (including biologics) and medical devices1.
You may also be interested in...
A new draft guideline explains how sponsors of subsequent-entry orally inhaled drug products can comply with the Canadian requirement for demonstrating equivalence to the reference product.
While good clinical practice inspectors in the UK and the US collaborate on matters of common interest, they say that mutual recognition is simply not possible.
Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”